MedTrace Logo

Studying DNA in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer

NCT00900289 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2013-02-13

No results posted yet for this study

Summary

RATIONALE: Studying tissue and blood samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients respond to treatment.

PURPOSE: This laboratory study is evaluating DNA to see how well it predicts response to treatment in patients with stage I, stage II, stage III, or stage IV ovarian epithelial cancer.

Conditions

Interventions

GENETIC

DNA methylation analysis

GENETIC

microarray analysis

GENETIC

polymerase chain reaction

OTHER

immunohistochemistry staining method

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • Liz-Anne Lewsley

    lead OTHER

Principal Investigators

  • Nadeem Siddiqui, MD · Scottish Gynaecological Cancer Trials Group

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-03-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00900289 on ClinicalTrials.gov